ArticleThe World Allergy Organization journal2025
Efficacy and safety of sublingual immunotherapy using a combination of
Article in The World Allergy Organization journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- House Dust Mite Sublingual Immunotherapy for Allergic Rhinoconjunctivitis: Comprehensive Review and Meta-Analytical Evidence.International archives of allergy and immunology · 2026Pooled it
- Probiotic therapy as adjuvant for allergic rhinitis: an overview of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Real-World Effectiveness and Safety of Triple-Mite SCIT With Dermatophagoides and Blomia tropicalis.Clinical and translational allergy · 2026Article
- Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.Journal of clinical medicine · 2026Review
- Efficacy and safety of Sublingual immunotherapy for allergic rhinitis: an overview of systematic reviews and meta analyses.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Diagnostic and therapeutic evaluation ofImmunotherapy · 2025Article
- Bibliometric and visual analysis of drug-specific immunotherapy from 1990 to 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergen immunotherapy is the only treatment that may modify the natural course of allergic diseases. Sublingual immunotherapy (SLIT) is a promising treatment, especially for children. Few studies currently exist related to optimal dosing for Methods: This was a double-blind, randomized, placebo-controlled trial of SLIT to treat house dust mite-induced Allergic Rhinitis (AR). A total of 65 patients, ages 12-16 years, were treated for 12 months and randomized into SLIT versus placebo. The SLIT group received a combination of Results: There was no significant difference in the number of adverse events between groups. The SLIT group showed a significant reduction in antihistamine use to control symptoms (p < 0.0001) compared to placebo. There was no significant change in serum total IgE, serum specific IgE, and IgG4 for either allergen when comparing the SLIT and placebo groups. Conclusion: After 1 year, SLIT using a dose of 1 mcg of Der p 1/day and 753 UBE of Blo t/day lowered the need for medications for break-through symptoms, with a good safety profile."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.